12:00 AM
 | 
Mar 16, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ASC-J9: Phase IIa data

Data from a double-blind, U.S. Phase IIa trial in 186 patients showed that 0.025% topical ASC-J9 twice daily reduced inflammatory lesions...

Read the full 82 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >